Acolbifene/prasterone

Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women.^[1] The formulation is intended for use by mouth.^[1] As of December 2017, it is in phase III clinical trials for this indication.^[1]

Acolbifene/prasterone

Combination of
Acolbifene	Selective estrogen receptor modulator
Prasterone	Androgen
Clinical data
Trade names	Femivia (tentative)
Other names	Prasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene
Routes of administration	By mouth

See also

• List of investigational sex-hormonal agents § Estrogenics